Tirzepatide Cuts Major Kidney Events 23% Versus Dulaglutide in SURPASS-CVOT
This pre-specified exploratory analysis provides the first randomised head-to-head kidney outcome data comparing a dual GIP/GLP-1 receptor agonist with a selective GLP-1 receptor agonist in type 2 diabetes and atherosclerotic cardiovascular disease.
📅 Journal publication: Jul 2026(online May 11, 2026)·Last updated: Nov 18, 2026
Tirzepatide outshines dulaglutide in kidney protection for diabetes.
Tirzepatide shows potential to better manage kidney outcomes in people with type 2 diabetes compared to dulaglutide. Tirzepatide reduced the risk of major kidney events by 23% compared to dulaglutide and slowed decline in eGFR. Findings suggest tirzepatide may be preferable for kidney protection in type 2 diabetes, but gastrointestinal side effects were more common. Tirzepatide may offer greater kidney protection than dulaglutide in diabetes.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Zoungas S, D'Alessio D, Pavo I, Bhatt DL, Buse JB, Prato SD, Kahn SE, Lincoff AM, McGuire DK, Nauck MA, Nissen SE, Sattar N, Zinman B, Ceriello A, Stechemesser L, Verhaegen A, Broder JC, Wolfe R, Miller D, Nishiyama H, Wang X, Weerakkody G, Wiese RJ, Nicholls SJ
Citation:Zoungas S, D'Alessio D, Pavo I, et al. A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. The lancet. Diabetes & endocrinology. 2026;14(7):544-557. doi:10.1016/S2213-8587(26)00032-X